Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with
Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who
stayed on the target size of 10 cm^2 for at least 8 weeks. This proportion was then compared
to historical data of the percentage of patients who could reach a rivastigmine capsule
target dose of 12 mg and stay on it at least 8 weeks.